Skip to main content

You are here

NNSA Signs Cooperative Agreement to Produce Molybdenum-99 in the United States without the use of Highly Enriched Uranium

WASHINGTON, D.C. – The National
Nuclear Security Administration’s (NNSA) Global Threat Reduction Initiative
announced today the signing of a cooperative agreement with NorthStar Medical
Radioisotopes, LLC, to further the development of accelerator-based technology
to produce molybdenum-99 (Mo-99) in the United States. 

cooperative agreement between NNSA and NorthStar, which totals $4.6 million and
is funded under a 50 percent/50 percent cost-share arrangement, will accelerate
the development of the NorthStar technology to produce Mo-99 without
proliferation-sensitive highly enriched uranium (HEU). The agreement would also support the goal of
ensuring a reliable domestic supply of this critical medical isotope for U.S.

The United States currently does not have a domestic
production capability for Mo-99 and must import 100 percent of its supply from
foreign producers, most of which use HEU in their production processes.  Over the past few years, technical
difficulties and shutdowns at the major Mo-99 production facilities have caused
severe supply shortages, which have greatly impacted the availability of Mo-99
to the medical community. The Mo-99 produced by NorthStar would provide
additional reliability for the U.S. supply.

As part of its nuclear nonproliferation mission, NNSA
works to accelerate the establishment of a diverse, reliable supply of the
critical medical isotope Mo-99, produced without the use of HEU, and this agreement is a significant step in those efforts.

“NNSA is
committed to supporting a diverse set of technologies for the establishment of
a reliable supply of molybdenum-99 produced here in the United States without the
use of highly enriched uranium,” said Deputy Administrator for Defense Nuclear
Nonproliferation Anne Harrington. “We are committed to supporting the technical
advancement of commercial partners to meet the needs of the U.S. medical
community while simultaneously advancing nonproliferation objectives and the
minimization of civilian use of HEU worldwide.”

NNSA has
partnered with four domestic commercial entities to accelerate the
establishment of a diverse, reliable supply of Mo-99 within the United States
that is not produced with HEU. NNSA also works with international producers to
assist in the conversion of their Mo-99 production facilities from the use of
HEU targets to LEU targets. These efforts are part of NNSA’s Global Threat
Reduction Initiative’s mission to minimize and, to the extent possible,
eliminate the use of HEU in civilian applications worldwide, including in
research reactors and medical isotope production facilities. 

For more information on NNSA’s efforts to establish
a reliable supply of Mo-99 without the use of HEU, click here.

Follow NNSA News on Facebook, Twitter, YouTube, and Flickr.

Established by Congress in
2000, NNSA is a semi-autonomous agency within the U.S. Department of Energy
responsible for enhancing national security through the military application of
nuclear science. NNSA maintains and enhances the safety, security, reliability
and performance of the U.S. nuclear weapons stockpile without nuclear testing;
works to reduce global danger from weapons of mass destruction; provides the
U.S. Navy with safe and effective nuclear propulsion; and responds to nuclear
and radiological emergencies in the United States and abroad.


NNSA Public Affairs (202) 586-7371